Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice.

Objective: To investigate the efficacy and safety outcomes of combination therapy used to optimize etanercept treatment in patients with psoriasis treated in real-life clinical practice.

Methods: Data from patients presenting with psoriasis, treated initially with etanercept monotherapy, were analysed retrospectively. Patients subsequently treated with combination therapy were further analysed.

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study.

Aim: To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis.

Methods: Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI).

Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-α agents.

Background: Clinical or quality of life assessments are currently available for psoriasis severity evaluation and therapeutic response. Laboratory scores focused to measure and follow treatment efficacy are lacking at present.

Methods: A microscopic and biomolecular score was designed to monitor skin disease severity and clinical response to anti-psoriatic treatments.

Immunologic biomarkers for clinical and therapeutic management of psoriasis.

Background: The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-α inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis.